Germany based 74 pt #FMF prospective non-interventional, multicenter observational study on Canakinumab – RELIANCE Registry
63% in remission in 2 yrs
serious adverse drug reactions – 1.56 per 100 patient years
@RheumNow #ACR22 abst#0138
StillsNow
An educational site for Physicians and Patients with Still's disease (systemic juvenile idiopathic arthritis), periodic fever syndromes and autoinflammatory diseases
